However, new research conducted by Sun Yat-sen University, located in south China's Guangdong Province, has uncovered that a protein called R9AP serves as a common receptor allowing EBV to infect both ...

Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV ... some forms of cancer and multiple ...

R9AP is a key receptor for entry of Epstein–Barr virus into human epithelial and B cells, and interacts directly with the viral glycoprotein gH/gL complex to mediate virus–host membrane fusion.

Epstein–Barr virus (EBV)-based biomarkers are used for nasopharyngeal carcinoma (NPC) screening in endemic regions. A recent prospective study describes the use of a new serological biomarker ...

Bristol-Myers Squibb has struck a deal granting rights to an “armed virus” targeting cancer from UK biotech, PsiOxus Therapeutics. BMS to pay up to $936m for NG-348.

Compared with women with ASC-US, the results of women with ASC-H on routine Pap are much more likely to have moderate to severe CIN, with estimates ranging widely from 24% to 94%. As a result ...